Frankfurt - Delayed Quote EUR

Merus N.V. (2GH.F)

32.60

-3.80

(-10.44%)

At close: 3:29:01 PM GMT+2

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonic

GlobeNewswire yesterday

MRUS
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a look at where Merus (NASDAQ:MRUS) stands against other high short interest stocks to buy now. Aditya Bhave, BofA Securities head of US Economics, joined ‘Power Lunch’ on CNBC on April […]

Insider Monkey 6 days ago

MRUS
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 14 days ago

BMRN

MRUS
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET. The webcast of th

GlobeNewswire 23 days ago

MRUS
Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

One thing we could say about the analysts on Merus N.V. ( NASDAQ:MRUS ) - they aren't optimistic, having just made a...

Simply Wall St. last month

MRUS
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Merus (MRUS) delivered earnings and revenue surprises of 56.84% and 22.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MRUS
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 - Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical dat

GlobeNewswire last month

MRUS
Merus to Present at Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerin

GlobeNewswire last month

MRUS
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

IOVA

MRUS
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to petosemtamab in combination with pembrolizuma

GlobeNewswire 2 months ago

MRUS
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET. The webcast of the presentation will be contemporaneously available on

GlobeNewswire 2 months ago

MRUS
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma

GlobeNewswire 2 months ago

MRUS
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a “challenging” year for biotech stocks, JPMorgan […]

Insider Monkey 3 months ago

MRUS
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

MRUS
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform technologies. Under the terms of the agreement, Biohaven is responsible for the pr

GlobeNewswire 3 months ago

MRUS

BHVN
Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

We recently published a list of 10 Jim Cramer Stocks to Watch in 2025. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other Jim Cramer stocks to watch in 2025. Jim Cramer in a latest program on CNBC commented on the bearish start of 2025 and […]

Insider Monkey 3 months ago

MRUS
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5. The phase 2, open

GlobeNewswire 4 months ago

MRUS
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other stocks under Jim Cramer’s lightning rounds’ spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following […]

Insider Monkey 4 months ago

MRUS
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-len

GlobeNewswire 4 months ago

MRUS
Merus Scores Its First FDA Approval For Lung Cancer Drug

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. Bizengri is Merus’s first approved medicine and is based on the proprietary Biclonics technology platform. Also Read: Merus Licenses US

Benzinga 4 months ago

MRUS

Performance Overview

Return	2GH.F	S&P 500 (^GSPC)
YTD	-17.68%	-6.75%
1-Year	-13.30%	+8.15%
3-Year	+63.00%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merus N.V. (2GH.F)

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus to Present at Upcoming Investor Conferences

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug

Performance Overview